Mesoblast gets a $110M life­line from Surg­Cen­ter De­vel­op­ment; uniQure still un­sure if gene ther­a­py spurred can­cer event

Mesoblast faced rough wa­ters in 2020, but on Mon­day were thrown a fi­nan­cial life­line.

The Aus­tralian stem cell ther­a­py play­er has raised $110 mil­lion in a pri­vate place­ment, the com­pa­ny an­nounced, of­fer­ing 60 mil­lion shares to the US in­vestor group Surg­Cen­ter De­vel­op­ment. Surg­Cen­ter re­ceived the shares at a 6.5% dis­count from Mesoblast’s clos­ing price on Feb. 25.

Mesoblast plans to use the funds to boost sup­ply of its lead can­di­date remestem­cel-L ahead of what they hope is a po­ten­tial ap­proval in pe­di­atric GvHD when they re­turn to the FDA, as well as ad­vanc­ing man­u­fac­tur­ing and de­vel­op­ment of their rexleme­stro­cel-L plat­form for chron­ic heart fail­ure and chron­ic low back pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER